Pillar Biosciences Raises $34.5M in Funding
NATICK, Mass., May 27, 2025 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have finalized $34.5M in funding, including a strategic investment from Illumina, structured financing from Soleus Capital and investments from existing investors.
Proceeds from this financing will be leveraged to advance Pillar's commercial activities including headcount and infrastructure to support biopharma partnerships and expand adoption of its distributable clinical testing kits.
"We are very pleased with our commercial growth over the past few years," said Gang Song, Founder and Executive Chairman of Pillar Biosciences. "We look forward to using this latest capital infusion to drive additional top-line growth as we move closer towards profitability."
The financial investment by Illumina further reinforces its strong partnership with Pillar which includes previous agreements announced in 2017 and 2023.
"Pillar Biosciences has become an important strategic partner to enable Illumina to provide an expanded menu of research and clinical NGS solutions, accelerating access to precision oncology," " said Ashley Van Zeeland, vice president of Corporate Development Illumina. "Pillar's rapid NGS targeted sequencing panels alongside Illumina's state-of-the-art sequencing and bioinformatics solutions delivers rapid, cost-effective genomic profiling of tumors, which is critical to advancing personalized therapy globally."
"Access to rapid NGS testing solutions is critical to advancing precision medicine in oncology. We see Pillar's technology as a market leader, helping laboratories across the globe more effectively streamline and consolidate their molecular testing platforms, enabling faster time to results," said Benjamin Lund from Soleus Capital. "Pillar has demonstrated strong commercial growth over the past few years, including multiple biopharma collaborations."
About Pillar Biosciences
Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar's NGS testing solutions are powered by its proprietary SLIMamp® and PiVAT® technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences has operations in Natick, MA. For more information visit pillarbiosci.com and connect with us on LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pillar-biosciences-raises-34-5m-in-funding-302464445.html
SOURCE Pillar Biosciences, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Tangent Launches Latest Innovation: High-Density Sheet
AURORA, Ill., June 5, 2025 /PRNewswire/ -- Tangent's latest product innovation, high-density sheet, is the ideal alternative material for extraordinary performance applications. This durable, all-weather HDPE sheet affords versatility of design unparalleled by traditional lumber. Affording product flexibility while eliminating unnecessary scrap, Tangent's high-density sheet gives consumers a quality product and builders a competitive advantage. Tangent's high-density sheet is water and moisture resistant, making life easy. No painting or staining is required, and cleaning requires only soap and water. Available in vibrant and trending colors: Black, White, Green, Gray, and Weathered Wood, these colors go beyond the industry standard with additional UV stabilizers to preserve the rich hues. Rigidity and broad span capacity make Tangent's high-density sheet ideal for many applications. This sheet material's durability is proven to withstand extreme force and resist insects, chemicals, and stains, all while handling like wood for build and design needs. Well suited for CNC machining, the product characteristics of Tangent's high-density sheet support clean, precise cuts, smooth edges, and surface routing. It can also be used with standard woodworking tools. Optimal sheet sizes and widths add versatility to Tangent's high-density sheet, helping avoid unnecessary scrap and affording limitless design potential. Strongly supporting waste stream diversion, recycled content is used within production, which is guaranteed by third-party GreenCircle™ Certification. Customization of sheet sizes makes Tangent's high-density sheet the obvious choice as the long-lasting solution for all outdoor projects. Offered in a classic matte, orange peel finish, this high-density sheet product complements the extensive line of profiles available from Tangent's extruded, dimensional lumber product. Max Tremblay, Tangent's Vice President of Engineering, noted, "After years of successfully utilizing our proprietary high-density polyethylene (HDPE) sheets to create millions of diverse furniture items, we are thrilled to announce our decision to extend our expertise to the broader market. With our commitment to quality and innovation, we have established ourselves as one of the largest extruders of HDPE products in North America. We are excited to make this versatile material widely available, empowering industries to collaboratively develop solutions for the challenges they face. Our HDPE sheets are not only durable and sustainable but also offer limitless possibilities for creative applications across various sectors. As we embark on this journey, we are dedicated to becoming the global leader in plastic extrusion products. This initiative marks a significant first step toward achieving that ambitious goal, and we look forward to partnering with businesses and innovators to drive progress in the industry." ABOUT TANGENT TECHNOLOGIESHeadquartered in Aurora, Illinois, Tangent is a leading manufacturer of synthetic lumber used for outdoor living, site amenities, structural applications, and marine decking. In recent years, synthetic lumber has become a leading substitute for traditional fabrication materials in outdoor living products and other applications, given its durability and aesthetics. Tangent uses a combination of post-consumer and post-industrial recycled waste streams as primary raw materials. Media Contact: Sandy Pace Email: Tangent Technologies, LLC Houston, TX 77441 View original content to download multimedia: SOURCE Tangent Materials Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Palo Alto Networks Hits $5B in NGS ARR: What's Fueling the Surge?
Palo Alto Networks PANW surpassed a key milestone during the third quarter of fiscal 2025, wherein the annual recurring revenues (ARR) for its next-generation security (NGS) solutions hit the $5 billion mark. In the third quarter, NGS ARR reached $5.09 billion, representing year-over-year growth of 34%.Palo Alto Networks had 130 customers with more than $5 million in NGS ARR at the end of the third quarter, up 41% year over year. Also, the customer count with more than $10 million in NGS ARR grew 63% to 44. In the third quarter, PANW reported that AI-related ARR now stands at approximately $400 million, 2.5 times higher than the year-ago quarter. The robust growth in NGS ARR can be attributed to its flagship XSIAM platform, which is gaining traction across enterprise customers. During the third quarter, bookings for XSIAM, an artificial intelligence (AI)-powered NGS platform, approached the nearly $1 billion mark on a trailing 12-month basis. The platform now has approximately 270 customers with an average ARR per customer of more than $1 million. XSIAM ARR grew more than 200% year over year in the third quarter, all within 30 months after XSIAM was made generally available to customers. With management targeting $15 billion in ARR by fiscal 2030, AI may be more than a tailwind, it could be the engine of PANW's next phase of growth. The company forecasts that its NGS ARR will contribute approximately 60-70% of the fiscal 2023 total targeted ARR. Competitors like CrowdStrike CRWD and SentinelOne S are also gaining ground through platform expansion and AI innovation. CrowdStrike ended its first quarter of fiscal 2026 with $4.44 billion in ARR, reflecting 22% year-over-year growth. The robust increase was fueled by the growing adoption of CrowdStrike's Falcon Flex subscription a small competitor, SentinelOne's ARR is also growing rapidly with reaching $948 million at the end of the first quarter of fiscal 2026. This represents a year-over-year rise of 24% fueled by growing adoption of SentinelOne's AI-first Singularity platform and Purple AI. Shares of Palo Alto Networks have gained 6.7% year to date compared with the industry's growth of 19.4%. Image Source: Zacks Investment Research From a valuation standpoint, PANW trades at a forward price-to-sales ratio of 12.6, below the Zacks Security industry's 14.47. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Palo Alto Networks' fiscal 2025 and 2026 earnings implies a year-over-year increase of approximately 15% and 11%, respectively. The estimates for fiscal 2025 have been revised upward in the past 30 days, while the same for fiscal 2026 has remained unchanged. Image Source: Zacks Investment Research PANW stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SentinelOne, Inc. (S) : Free Stock Analysis Report Palo Alto Networks, Inc. (PANW) : Free Stock Analysis Report CrowdStrike (CRWD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
ISG to Evaluate Medical Device Service, Solution Providers
Upcoming ISG Provider Lens™ reports will cover providers helping companies integrate new technologies to make devices more capable, compliant and interoperable STAMFORD, Conn., June 05, 2025--(BUSINESS WIRE)--Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study evaluating digital transformation service and solution providers supporting the medical devices industry, exploring how they help device makers address technology challenges while accelerating innovation and time to market. The study results will be published in two comprehensive ISG Provider Lens™ reports, titled Medical Device Digital Services, covering the U.S. and European markets, respectively, and scheduled to be released in November 2025. The study will examine providers offering medical device companies end-to-end digital engineering and product development services; strategic consulting, quality assurance and regulatory compliance services; and digital solutions for post-market activities. In particular, it will assess provider ability to address technology challenges such as data interoperability and cybersecurity. Enterprise buyers will be able to use information from the reports to evaluate their current vendor relationships, potential new engagements and available offerings, while ISG advisors use the information to recommend providers to the firm's buy-side clients. The medical device industry is embracing digital transformation by integrating AI, IoT and cloud technologies. These advancements enhance real-time monitoring and predictive diagnostics, facilitate improved clinical decisions and transform traditional hardware-centric models into dynamic, data-driven ecosystems. "Medical devices are quickly evolving to meet the new requirements of patient-centric healthcare," said Iain Fisher, director, ISG Provider Lens Research. "Device makers need to collaborate with providers on innovation and improve outcomes to remain competitive in the market." ISG has distributed surveys to more than 100 providers of medical device services and solutions. Working in collaboration with ISG's global advisors, the research team will produce three quadrants representing the digital services and solutions most commonly used by medical device companies, based on ISG's experience working with its clients. The three quadrants are: Digital Engineering and Product Development, evaluating providers with expertise in designing and enhancing interconnected, software-driven, compliant medical devices. Providers are assessed on their abilities to apply emerging technologies such as AI, ML, digital twins and edge computing to accelerate innovation, ensure compliance and reduce time to market. Regulatory Compliance, Strategy and Quality Assurance, assessing providers that help medical device manufacturers navigate global regulatory frameworks and align engineering initiatives with go-to-market objectives. Providers implement cybersecurity and data protection strategies, ensuring product and patient safety in connected and software-driven environments. Post-Market Digital Enablement, covering providers that deliver digital solutions for continuous monitoring, device tracking and telehealth integration. Providers focus on developing and integrating remote patient monitoring systems, analytics and post-market surveillance tools. Geographically focused reports from the study will cover digital services and solutions offered to medical device companies in the U.S. and Europe. ISG analysts Rohan Sinha (U.S.) and Sneha Jayanth (Europe) will serve as authors of the reports. A list of identified providers and vendors and further details on the study are available in this digital brochure. Companies not listed as digital transformation solution and service providers can contact ISG and ask to be included in the study. All 2025 ISG Provider Lens™ evaluations feature expanded customer experience (CX) data that measures actual enterprise experience with specific provider services and solutions, based on ISG's continuous CX research. Enterprise customers wishing to share their experience about a specific provider or vendor are encouraged to complete this online survey. Participants will receive a copy of this report in return for their feedback. About ISG Provider Lens™ Research The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments. View source version on Contacts Press Contacts: Laura Hupprich, ISG+1 203 517 Julianna Sheridan, Matter Communications for ISG+1 978-518-4520isg@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
